Comparison
CJC-1295 vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
no data
80714-61-0
Molecular weight
3647.3 g/mol
813.92 g/mol
Half-life
144 h
0.3 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACMet-Glu-His-Phe-Pro-Gly-ProMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
4
of which in humans
2
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
3
1